Dermatology · Topical ImmunomodulatorRegulatory Approvalregulatorymid-term

Apotex submits supplemental ANDA for Imiquimod

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/1/2026, 6:30:58 AM

Assessment confidence: 66% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The submission of a supplemental ANDA for Imiquimod by Apotex is significant as it may intensify competition in the dermatology market. Pharma strategy teams should closely monitor the FDA's review process and assess potential impacts on market dynamics and pricing strategies. Regulatory context from FDA (FDA AP — IMIQUIMOD (SUPPL)) supports the near-term read. Assessment grounded in 20 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential impact on market share and pricing strategies for Imiquimod products. The strongest clinical anchor is Suction Mini-PCNL Versus Standard PCNL for the Management of 2-4cm Kidney Stones (ClinicalTrials.gov), moderate corpus alignment. In Dermatology · Topical Immunomodulator, 8 regulatory and 1 competitive items passed relevance filtering for Apotex.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). This submission may enhance Apotex's position in the dermatology market, potentially increasing competition against branded and generic versions of Imiquimod.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — IMIQUIMOD (SUPPL) (FDA). Entity match (apotex); Regulatory pathway relevance (nda). The supplemental application will undergo FDA review, which could lead to changes in approval timelines and market entry strategies for competing products.

Key Risks

Elevated medium regulatory exposure for Apotex could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Increased competition from Apotex could pressure pricing and market share for existing Imiquimod products, affecting revenue streams for current market players.
Upside for Apotex may improve if Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Apotex may improve if Controlling Hyperactive Immunity With Long-lived Lymphocytes (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the potential impact on market share and pricing strategies for Imiquimod products.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review timeline and any subsequent approval announcements for this supplemental application.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — IMIQUIMOD (SUPPL)
FDAhigh relevance
Entity match (apotex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Entity match (apotex); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — RUXOLITINIB (ORIG)
FDAhigh relevance
Entity match (apotex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ACYCLOVIR (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ACYCLOVIR (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CARBIDOPA AND LEVODOPA (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FLUOCINOLONE ACETONIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CICLOPIROX (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Suction Mini-PCNL Versus Standard PCNL for the Management of 2-4cm Kidney Stones
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of Foot Massage on Pain and Analgesic Consumption in Total Knee Prosthesis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Controlling Hyperactive Immunity With Long-lived Lymphocytes
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Effects of caffeine gum on same-day and subsequent neuromuscular performance under a standardized resistance-priming condition in male basketball players.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of extended-release topical polyhexanide in Staphylococcus aureus-induced murine dermatitis model characterized by IL-36 expression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006-2025).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Apotex
Imiquimod

Commercial impact

medium

Increased competition from Apotex could pressure pricing and market share for existing Imiquimod products, affecting revenue streams for current market players.

Regulatory impact

medium

The supplemental application will undergo FDA review, which could lead to changes in approval timelines and market entry strategies for competing products.

What to watch

Monitor the FDA's review timeline and any subsequent approval announcements for this supplemental application.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.